Department of Neuroscience, Mental Health, and Sensory Organs, "Sapienza" University of Rome, Rome, Italy.
Department of Human Neurosciences, "Sapienza" University of Rome, Rome, Italy.
Int Psychogeriatr. 2022 Jun;34(6):529-542. doi: 10.1017/S1041610220004056. Epub 2021 Feb 15.
To perform a meta-analysis of clinical studies on the differences in treatment or research decision-making capacity among patients with Mild Cognitive Impairment (MCI), Alzheimer's disease (AD), and healthy comparisons (HCs).
A systematic search was conducted on Medline/Pubmed, CINAHL, PsycINFO, Web of Science, and Scopus. Standardized mean differences and random-effects model were used in all cases.
The United States, France, Japan, and China.
Four hundred and ten patients with MCI, 149 with AD, and 368 HCs were included.
The studies we included in the analysis assessed decisional capacity to consent by the MacArthur Competence Assessment Tool for Treatment (MAcCAT-T), MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR), Capacity to Consent to Treatment Instrument (CCTI), and University of California Brief Assessment of Capacity to Consent (UBACC).
We identified 109 potentially eligible studies from 1672 records, and 7 papers were included in the meta-analysis. The meta-analysis showed that there was significant impairment in a decision-making capacity in MCI patients compared to the HCs group in terms of Understanding (SMD = -1.04, 95% CI: -1.31 to -0.77, < 0.001; = 52%, = 0.07), Appreciation (SMD = -0.51, 95% CI: -0.66 to -0.36, < 0.001; = 0%, = 0.97), and Reasoning (SMD = -0.62, 95% CI: -0.77, -0.47, < 0.001; =0%, =0.46). MCI patients scored significantly higher in Understanding (SMD = 1.50, 95% CI: 0.91, 2.09, = 0.01, = 78%, = 0.00001) compared to patients affected by AD.
Patients affected by MCI are at higher risk of impaired capacity to consent to treatment and research compared to HCs, despite being at lower risk compared to patients affected by AD. Clinicians and researchers need to carefully evaluate decisional capacity in MCI patients providing informed consent.
对轻度认知障碍(MCI)、阿尔茨海默病(AD)患者与健康对照者(HCs)在治疗或研究决策能力方面的差异进行临床研究的荟萃分析。
系统检索 Medline/Pubmed、CINAHL、PsycINFO、Web of Science 和 Scopus。所有情况下均采用标准化均数差和随机效应模型。
美国、法国、日本和中国。
纳入 410 例 MCI 患者、149 例 AD 患者和 368 例 HCs。
我们纳入的研究采用 MacArthur 治疗决策能力评估工具(MAcCAT-T)、MacArthur 临床研究决策能力评估工具(MacCAT-CR)、同意治疗能力量表(CCTI)和加利福尼亚大学简短同意能力评估(UBACC)评估决策能力。
从 1672 条记录中确定了 109 项潜在合格研究,7 篇论文纳入荟萃分析。荟萃分析显示,与 HCs 组相比,MCI 患者在理解(SMD=-1.04,95%CI:-1.31 至-0.77, < 0.001; = 52%, = 0.07)、欣赏(SMD=-0.51,95%CI:-0.66 至-0.36, < 0.001; = 0%, = 0.97)和推理(SMD=-0.62,95%CI:-0.77 至-0.47, < 0.001; = 0%, = 0.46)方面的决策能力明显受损。与 AD 患者相比,MCI 患者在理解方面的得分显著更高(SMD=1.50,95%CI:0.91,2.09, = 0.01, = 78%, = 0.00001)。
与 HCs 相比,MCI 患者在同意治疗和研究方面的能力受损风险更高,尽管与 AD 患者相比,他们的风险较低。临床医生和研究人员需要仔细评估 MCI 患者在提供知情同意时的决策能力。